595 related articles for article (PubMed ID: 24450618)
1. Leishmaniasis in immunosuppressed individuals.
van Griensven J; Carrillo E; López-Vélez R; Lynen L; Moreno J
Clin Microbiol Infect; 2014 Apr; 20(4):286-99. PubMed ID: 24450618
[TBL] [Abstract][Full Text] [Related]
2. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.
Eichenberger A; Buechi AE; Neumayr A; Hatz C; Rauch A; Huguenot M; Diamantis-Karamitopoulou E; Staehelin C
BMC Infect Dis; 2017 Jan; 17(1):81. PubMed ID: 28095796
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Darcis G; Van der Auwera G; Giot JB; Hayette MP; Tassin F; Arrese Estrada J; Cnops L; Moutschen M; de Leval L; Leonard P
BMC Infect Dis; 2017 Jul; 17(1):478. PubMed ID: 28687071
[TBL] [Abstract][Full Text] [Related]
4. Leishmaniasis.
Herwaldt BL
Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
[TBL] [Abstract][Full Text] [Related]
5. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
Zijlstra EE
PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
[TBL] [Abstract][Full Text] [Related]
6. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient.
Mirzabeigi M; Farooq U; Baraniak S; Dowdy L; Ciancio G; Vincek V
J Cutan Pathol; 2006 Oct; 33(10):701-4. PubMed ID: 17026523
[TBL] [Abstract][Full Text] [Related]
9. [Visceral leishmaniasis in patient with HIV infection].
Olea P; Pinilla J
Rev Chilena Infectol; 2013 Apr; 30(2):216-20. PubMed ID: 23677161
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous leishmaniasis in the returning traveler.
Magill AJ
Infect Dis Clin North Am; 2005 Mar; 19(1):241-66, x-xi. PubMed ID: 15701556
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
[TBL] [Abstract][Full Text] [Related]
12. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Patole S; Burza S; Varghese GM
Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662
[TBL] [Abstract][Full Text] [Related]
13. Clinical aspects of visceral leishmaniasis in HIV infection.
Jarvis JN; Lockwood DN
Curr Opin Infect Dis; 2013 Feb; 26(1):1-9. PubMed ID: 23221770
[TBL] [Abstract][Full Text] [Related]
14. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
Ali A
Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
[TBL] [Abstract][Full Text] [Related]
15. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
16. Leishmaniasis chemotherapy--challenges and opportunities.
Croft SL; Olliaro P
Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
[TBL] [Abstract][Full Text] [Related]
17. Leishmaniasis.
Burza S; Croft SL; Boelaert M
Lancet; 2018 Sep; 392(10151):951-970. PubMed ID: 30126638
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
[TBL] [Abstract][Full Text] [Related]
19. Leishmaniasis.
Moore EM; Lockwood DN
Clin Med (Lond); 2011 Oct; 11(5):492-7. PubMed ID: 22034715
[TBL] [Abstract][Full Text] [Related]
20. Relapsing visceral leishmaniasis in a HIV-1 infected patient with advanced disease.
Standaert D; Laurent F; Jonckheere S; Scheiff JM; Vandercam B; Yombi JC
Acta Clin Belg; 2013; 68(2):124-7. PubMed ID: 23967722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
